Executive leadership at CytoDyn.
Board of directors at CytoDyn.
Research analysts covering CytoDyn.
Recent press releases and 8-K filings for CYDY.
CytoDyn Secures $30 Million Funding Commitment from Yorkville Advisors
CYDY
- CytoDyn Inc. has secured a $30 million funding commitment from Yorkville Advisors Global through a Standby Equity Purchase Agreement.
- Under the agreement, CytoDyn has the discretionary right to sell up to $30 million of its common stock to Yorkville over the next 36 months, with no obligation to utilize the full amount and no warrants or derivatives associated with the arrangement.
- The proceeds from these sales are expected to be used for working capital, general corporate purposes, and debt repayment.
- As consideration for Yorkville's commitment, CytoDyn paid a $25,000 structuring fee and will pay a 1.00% commitment fee (of the $30 million commitment) in common stock.
Nov 3, 2025, 1:38 PM
CytoDyn Secures Funding Commitment
CYDY
New Projects/Investments
- CytoDyn Inc. secured a $30 million funding commitment from Yorkville Advisors Global.
- Under the agreement, CytoDyn has the right to sell, and Yorkville has the obligation to purchase up to $30 million worth of CytoDyn’s common stock over the next 36 months.
- CytoDyn retains sole discretion over the timing of sales, and there are no warrants, derivatives, or other share classes associated with the arrangement.
- The company is not obligated to utilize any of the $30 million available, with no minimum commitments or penalties.
- The funding will be utilized to further develop the program centered around leronlimab's ability to upregulate PD-L1.
Nov 3, 2025, 1:30 PM
CytoDyn Provides Update on Leronlimab Oncology Program and Appoints New CFO
CYDY
CFO Change
New Projects/Investments
- CytoDyn Inc. has appointed Robert E. Hoffman as its new Chief Financial Officer.
- The company is advancing leronlimab in oncology, with data presented at ESMO suggesting it induces PD-L1 expression in metastatic triple-negative breast cancer (mTNBC), potentially creating synergy with immune checkpoint inhibitors (ICIs).
- A follow-up Phase II proof of concept protocol for PD-L1-negative mTNBC patients will be submitted, proposing a regimen of leronlimab with standard chemotherapy, followed by leronlimab with an ICI.
- Pooled follow-up data from 28 mTNBC patients showed promising overall survival rates of 17.9% at both years 3 and 4.
- CytoDyn is also progressing other clinical initiatives, including amendments to its colorectal cancer study, an advancing investigator-initiated glioblastoma study, and FDA/IRB approval for an Alzheimer's study.
Sep 30, 2025, 12:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more